Patents Assigned to AstraZeneca AB
  • Chemical compounds
    Patent number: 10125135
    Abstract: The specification relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: November 13, 2018
    Assignee: AstraZeneca AB
    Inventors: Bin Yang, Jeffrey Gilbert Varnes, James Stewart Scott, Thomas Andrew Moss, Daniel Hillebrand O'Donovan, Johannes Wilhelmus Maria Nissink, Samantha Jayne Hughes, Bernard Christophe Barlaam
  • Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer
    Publication number: 20180318287
    Abstract: The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where x, R1, R2, R3, R4 and R5 have any of the meanings defined herein. The specification also relates to the use of compounds of Formula (I) and salts thereof to treat or prevent ATM mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising substituted imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; and intermediates useful in such manufacture.
    Type: Application
    Filed: November 2, 2016
    Publication date: November 8, 2018
    Applicant: ASTRAZENECA AB
    Inventors: Kurt Gordon PIKE, Bernard Christophe BARLAAM, Thomas Anthony HUNT, Andrew John EATHERTON
  • Arginase inhibitors and methods of use
    Patent number: 10118936
    Abstract: The present invention is directed to arginase inhibitor compounds of formula IA or formula IB: or a pharmaceutically acceptable salt thereof, compositions containing these compounds, and methods of their use for the treatment and diagnosis of conditions characterized by upregulation of arginase, abnormally high arginase activity, or by abnormally low nitric oxide synthase activity.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: November 6, 2018
    Assignees: The Trustees of the University of Pennsylvania, AstraZeneca AB
    Inventors: David W. Christianson, Bruce Edward Tomczuk, Richard Scott Pottorf, Andrew Vargha Colasanti, Gary Lee Olson
  • Protein kinase B inhibitors
    Patent number: 10059714
    Abstract: The invention relates to a novel group of compounds of Formula (I) or salts thereof: wherein Y, Z1, Z2, R1, R4, R5 and n are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through protein kinase B (PKB) such as cancer. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by PKB using said compounds and methods for preparing compounds of Formula (I).
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: August 28, 2018
    Assignee: AstraZeneca AB
    Inventors: Paul David Johnson, Andrew Leach, Richard William Arthur Luke, Zbigniew Stanley Matusiak, Jeffrey James Morris
  • PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS
    Publication number: 20180237439
    Abstract: The present application relates to novel compounds of formula (I) to their utility in treating and/or preventing clinical conditions including cardiovascular diseases (CVD), to methods for their therapeutic use, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Application
    Filed: May 3, 2016
    Publication date: August 23, 2018
    Applicant: ASTRAZENECA AB
    Inventors: Johan Olof BRODDEFALK, Hans Fredrik EMTENÄS, Kenneth Lars GRANBERG, Malin Anita LEMURELL, Daniel Tor PETTERSEN, Alleyn Thomas PLOWRIGHT, Lars Johan Andreas ULANDER
  • Chemical Compounds
    Publication number: 20180237443
    Abstract: The present disclosure concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1, R2 and R3 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cancer.
    Type: Application
    Filed: January 18, 2018
    Publication date: August 23, 2018
    Applicant: AstraZeneca AB
    Inventors: Clifford David Jones, Richard Andrew Ward, Mark Andrew Graham, Steven Swallow, Andrew Hornby Dobson, James Francis McCabe
  • Compounds and their use as BACE inhibitors
    Patent number: 10053453
    Abstract: The present application relates to compounds of formula (I), (Ia), or (Ib) and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing A?-related pathologies such as Down's syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia, including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: August 21, 2018
    Assignee: AstraZeneca AB
    Inventors: Roland Bürli, Mark E. Duggan, Jörg Holenz, Patrik Johansson, Karin Kolmodin, Philip Vellacott Thorne, Michael John McKenzie
  • [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES
    Publication number: 20180230158
    Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1, R2 and n have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use as anti-proliferative and/or cell-killing agents.
    Type: Application
    Filed: April 11, 2018
    Publication date: August 16, 2018
    Applicant: AstraZeneca AB
    Inventors: Robert Hugh BRADBURY, Alfred Arthur Rabow, Michael James Waring, James Francis McCabe, Steven Christopher Glossop, Arshed Mahmood, Zoe Ann Cotter
  • Therapeutic polymeric nanoparticles and methods of making and using same
    Patent number: 10047072
    Abstract: Described herein are polymeric nanoparticles that include a therapeutic agent which is 2-(3-((7-(3-(ethyl(2-hydroxyethyl)amino)propoxy)quinazolin-4-yl)amino)-1H-pyrazol-5-yl)-N-(3-fluorophenyl)acetamide (also known as AZD1152 hqpa) or a pharmaceutically acceptable salt thereof, and methods of making and using such therapeutic nanoparticles.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: August 14, 2018
    Assignee: ASTRAZENECA AB
    Inventors: Marianne Bernice Ashford, James Martin Nolan, III, Eyoung Shin, Young-Ho Song, Greg Troiano, Hong Wang
  • 1,3,4-thiadiazole compounds and their use in treating cancer
    Patent number: 10040789
    Abstract: A compound of Formula (I): or a pharmaceutically acceptable salt thereof, is described. Q can be pyridazin-3-yl, 6-fluoropyridazin-3-yl; R1 can be H; R2 and R3 can each independently be C1-C6 alkyl, or R2 and R3 taken together are —(CH2)3—; or R1 and R2 taken together can be —(CH2)2— and R3 can be —CH3; R4 halo, —CH3, —OCH3, —OCHF2, —OCF3, or —CN; and n can be 0, 1, or 2. The compound of formula (I) can inhibit glutaminase, e.g., GLS1.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: August 7, 2018
    Assignees: AstraZeneca AB, Cancer Research Technology Limited
    Inventors: David Robert Perkins, Maurice Raymond Verschoyle Finlay, Johannes Wilhelmus Maria Nissink, Piotr Antoni Raubo, Peter Duncan Smith, Andrew Bailey
  • Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d] pyrimidin-4-y1) piperidine-4-carboxamide
    Patent number: 10039766
    Abstract: The present invention discloses certain new solid state forms of (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide, processes for preparing such forms, pharmaceutical compositions comprising them, and the use of such forms in therapy.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: August 7, 2018
    Assignee: AstraZeneca AB
    Inventor: Gary Peter Tomkinson
  • 1,3,4-thiadiazole compounds and their use in treating cancer
    Patent number: 10040788
    Abstract: The specification relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where Q, R, R1 and R2 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent GLS1 mediated disease, including cancer. The specification further relates to crystalline forms of compounds of Formula (I) and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating GLS1 kinase mediated disease, including cancer, using such compounds and salts.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: August 7, 2018
    Assignees: AstraZeneca AB, Cancer Research Technology Limited
    Inventors: Maurice Raymond Verschoyle Finlay, Chukuemeka Tennyson Ekwuru, Mark David Charles, Piotr Antoni Raubo, Jonathan James Gordon Winter, Johannes Wilhelmus Maria Nissink
  • Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptors
    Patent number: 10016483
    Abstract: The present disclosure relates to methods of treating, ameliorating or preventing a disorder comprising administering a therapeutically effective amount of a composition comprising a protein which inhibits the ligand of Uniprot #P05112 and/or the ligand of Uniprot #P35225 from binding to their respective receptors to a subject in need thereof. In some embodiments, the disorder is preferably associated with an increase of the Th2 immune response. In some embodiments, administration is preferably locally to the lung in order to treat, ameliorate or prevent allergic asthma, rhinitis, conjunctivitis, lung fibrosis, cystic fibrosis, chronic obstructive pulmonary disease, pulmonary alveolar proteinosis or adult respiratory distress syndrome.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: July 10, 2018
    Assignees: PIERIS PHARMACEUTICALS GMBH, ASTRAZENECA AB
    Inventors: Andreas Hohlbaum, Laurent Audoly, Beverly Koller
  • 2-(2,4,5-substituted-anilino)pyrimidine compounds
    Patent number: 10017493
    Abstract: The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exon19 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of said compounds and to methods of treatment of diseases mediated by various different forms of EGFR using said compounds and salts thereof.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: July 10, 2018
    Assignee: AstraZeneca AB
    Inventors: Sam Butterworth, Maurice Raymond Verschoyle Finlay, Richard Andrew Ward, Heather Marie Redfearn
  • Benzoxazinone amides as mineralocorticoid receptor modulators
    Patent number: 10017502
    Abstract: Disclosed are certain derivatives of benzoxazinone amides of formula (I), or pharmaceutically acceptable salts thereof, (Formula (I)) that act as mineralocorticoid (MR) receptor modulators that may reduce oxidative stress in endothelium and hence improve vascular function, to methods for their potential therapeutic use, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: July 10, 2018
    Assignee: AstraZeneca AB
    Inventors: Gavin O'Mahony, Michael Kossenjans, Karl Edman, Johan Kajanus, Carl Anders Hogner, Philip Cornwall, Andrew Turner
  • 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
    Patent number: 10016430
    Abstract: There are disclosed certain 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one compounds of formula (I), and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of cardiovascular disorders such as heart failure and coronary artery disease related conditions.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: July 10, 2018
    Assignee: AstraZeneca AB
    Inventors: Tord Bertil Inghardt, Petra Johannesson, Ulrik Jurva, Erik Michaelsson, Eva-Lotte Lindstedt-Alstermark, Nicholas Tomkinson, Jeffrey Paul Stonehouse, Li-Ming Gan
  • Compounds
    Patent number: 10011566
    Abstract: The present specification provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ROR? and/or ROR?t mediated disease state.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: July 3, 2018
    Assignee: AstraZeneca AB
    Inventors: Frank Narjes, Roine Ingemar Olsson, Stefan Von Berg, Sarah Lever
  • MALEATE SALTS OF A QUINAZOLINE DERIVATIVE USEFUL AS AN ANTIANGIOGENIC AGENT
    Publication number: 20180170913
    Abstract: The present invention relates to AZD2171 maleate salt, to particular crystalline forms of AZD2171 maleate salt, to processes for their preparation, to pharmaceutical compositions containing them as active ingredient, to their use in the manufacture of medicaments for use in the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals such as humans, and to their use in methods for the treatment of disease states associated with angiogenesis and/or increased vascular permeability.
    Type: Application
    Filed: December 28, 2017
    Publication date: June 21, 2018
    Applicant: AstraZeneca AB
    Inventor: James MCCABE
  • 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS
    Publication number: 20180162832
    Abstract: The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exon19 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of said compounds and to methods of treatment of diseases mediated by various different forms of EGFR using said compounds and salts thereof.
    Type: Application
    Filed: July 13, 2017
    Publication date: June 14, 2018
    Applicant: AstraZeneca AB
    Inventors: Sam Butterworth, Maurice Raymond Verschoyle Finlay, Richard Andrew Ward, Heather Marie Redfearn
  • 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents
    Patent number: RE47047
    Abstract: The present invention relates to compounds of formula I, processes for their production and their use as anti-inflammatory agents.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: September 18, 2018
    Assignees: ASTRAZENECA AB, BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Markus Berger, Hartmut Rehwinkel, Thomas Zollner, Ekkehard May, Jorma Hassfeld, Heike Schaecke